Dopamine Pathways

Though it’s often referred to as the “feel-good” chemical, its function in the brain is much more complex and nuanced than most people realize. This is largely why it contributes to certain psychiatric disorders. In psychiatry, understanding the 4 dopamine pathways is central to understanding and addressing conditions including schizophrenia, depression, ADHD, and substance use disorders.

The Four Major Dopamine Pathways:
1. Mesolimbic Pathway
The mesolimbic pathway is often referred to as the reward pathway because of its involvement in reward processing. It runs from the ventral tegmental area (VTA) to the nucleus accumbens. Dysregulation of this pathway is implicated in addiction and psychosis, which is supported by many studies.
2. Mesocortical Pathway
This pathway connects the VTA to the prefrontal cortex and is involved in executive functions: attention, decision making, and emotional regulation. Hypoactivity in this pathway is associated with the negative and cognitive symptoms of schizophrenia.
3. Nigrostriatal Pathway
This pathway originates in the substantia nigra and projects into the striatum. It is essential for motor control, which is why it is most known for its role in Parkinson’s disease. This disease is associated with the degeneration of dopamine-producing neurons, leading to tremors, rigidity, and bradykinesia.
4. Tuberoinfundibular Pathway
This pathway connects the hypothalamus to the pituitary gland and regulates the secretion of prolactin. Dopamine acts as a prolactin-inhibiting factor. Disruptions in this pathway can result in hormonal imbalances.

Dopamine and Psychiatric Disorders:
● Schizophrenia: Elevated levels of dopamine in the mesolimbic pathway are associated with hallucinations and delusions. Reduced activity in the mesocortical pathway underlie negative symptoms and cognitive impairment.
● Depression: Though this disorder is traditionally associated with serotonin, emerging evidence suggests that decreased dopamine transmission in reward pathways may contribute to anhedonia and low motivation.
● ADHD: Reduced dopamine availability in the prefrontal cortex and striatum is linked to inattention and impulsivity. Stimulant medications like methylphenidate increase synaptic dopamine and improve symptoms.
● Substance Use Disorders: Drugs such as cocaine and methamphetamine impact the mesolimbic pathway, leading to excessive dopamine release and reinforcing the use of drugs.

Dopamine pathways are central to how we think, feel pleasure, and regulate behavior. By understanding their role in psychiatric disorders, researchers and clinicians can offer better target treatments that restore dopamine balance and improve patients’ quality of life. Advances in imaging and pharmacology continue to expand our understanding of how these neuropsychiatric systems function and fail.

 

reviewed by Nicolas Sikaczowski, DO Board Certified Adult & Child Psychiatrist

Sources:
Berridge, K. C., & Robinson, T. E. (1998). What is the role of dopamine in reward: hedonic
impact, reward learning, or incentive salience? Brain Research Reviews, 28(3), 309–369.
https://doi.org/10.1016/S0165-0173(98)00019-8
Arnsten, A. F. T., & Rubia, K. (2012). Neurobiological circuits regulating attention, cognitive
control, motivation, and emotion: Disruptions in neurodevelopmental psychiatric disorders.
Journal of the American Academy of Child and Adolescent Psychiatry, 51(4), 356–367.
https://doi.org/10.1016/j.jaac.2012.01.008
Dauer, W., & Przedborski, S. (2003). Parkinson’s disease: Mechanisms and models. Neuron,
39(6), 889–909. https://doi.org/10.1016/S0896-6273(03)00568-3
Ben-Jonathan, N., & Hnasko, R. (2001). Dopamine as a prolactin (PRL) inhibitor. Endocrine
Reviews, 22(6), 724–763. https://doi.org/10.1210/edrv.22.6.0451
Howes, O. D., & Kapur, S. (2009). The dopamine hypothesis of schizophrenia: Version III – The
final common pathway. Schizophrenia Bulletin, 35(3), 549–562.
https://doi.org/10.1093/schbul/sbp006
Treadway, M. T., & Zald, D. H. (2011). Reconsidering anhedonia in depression: Lessons from
translational neuroscience. Neuroscience & Biobehavioral Reviews, 35(3), 537–555.
https://doi.org/10.1016/j.neubiorev.2010.06.006
Volkow, N. D., et al. (2009). Motivation deficit in ADHD is associated with dysfunction of the
dopamine reward pathway. Molecular Psychiatry, 14(3), 299–307.
https://doi.org/10.1038/mp.2008.77
Koob, G. F., & Volkow, N. D. (2010). Neurocircuitry of addiction. Neuropsychopharmacology,
35(1), 217–238. https://doi.org/10.1038/npp.2009.110